{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:43:48Z","timestamp":1776426228015,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patent foramen ovale (PFO) closure is recommended in selected patients with a\u00a0cryptogenic stroke and a\u00a0PFO, as multiple randomized controlled trials (RCTs) have shown superiority of PFO closure over medical therapy in reducing recurrent stroke risk. However, follow-up data outside clinical trials remains scarce. The aim of this study is to evaluate the stroke\/transient ischemic attack (TIA) recurrence after PFO closure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 242 patients who underwent PFO closure at the University Medical Centre Groningen (UMCG) between February 2016 and June 2023, because of a\u00a0cryptogenic stroke, TIA, or peripheral embolism, were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During a\u00a0median follow-up of 3.1\u00a0years (IQR: 1.9\u20134.3), a\u00a0total of 5\u00a0recurrent strokes (0.70 per 100 person-years) and 11\u00a0recurrent TIAs (1.54 per 100 person-years) were documented. In patients with a\u00a0recurrent neurological event, hypertension was more prevalent (30.8% vs.\u00a09.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.040). Atrial fibrillation (AF) or atrial flutter was seen in 5.7% of the patients. Other adverse events were rare.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, the rate of recurrent stroke\/TIA after PFO closure was low, but higher than reported in previous studies. These elevated values are primarily due to the higher risk of recurrent TIA, as the recurrent stroke risk in our cohort is comparable to that reported in RCTs. Hypertension was significantly associated with the recurrence of a\u00a0stroke\/TIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12471-026-02042-w","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:02:10Z","timestamp":1775638930000},"page":"170-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stroke and transient ischemic attack recurrence after PFO closure in patients with cryptogenic embolism"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2136-9347","authenticated-orcid":false,"given":"Matthijs W.","family":"Kanon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke S.","family":"Hoendermis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik A.","family":"Badings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"van Wijngaarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"10069","key":"2042_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(16)30962-X","volume":"389","author":"GJ Hankey","year":"2017","unstructured":"Hankey\u00a0GJ. Stroke. Lancet. 2017;389(10069):641\u201354.","journal-title":"Lancet"},{"issue":"13","key":"2042_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.4244\/EIJ-D-18-00622","volume":"14","author":"C Pristipino","year":"2019","unstructured":"Pristipino\u00a0C, Sievert\u00a0H, D\u2019Ascenzo\u00a0F, et\u00a0al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention. 2019;14(13):1389\u2013402.","journal-title":"EuroIntervention"},{"issue":"4","key":"2042_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/23969873241247978","volume":"9","author":"V Caso","year":"2024","unstructured":"Caso\u00a0V, Turc\u00a0G, Abdul-Rahim\u00a0AH, et\u00a0al. European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke. Eur Stroke\u00a0J. 2024;9(4):800\u201334.","journal-title":"Eur Stroke J"},{"issue":"20","key":"2042_CR4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","volume":"71","author":"PH Lee","year":"2018","unstructured":"Lee\u00a0PH, Song\u00a0J, Kim\u00a0JS, et\u00a0al. Cryptogenic stroke and high-risk patent foramen ovale. J\u00a0Am Coll Cardiol. 2018;71(20):2335\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2042_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L S\u00f8ndergaard","year":"2017","unstructured":"S\u00f8ndergaard\u00a0L, Kasner\u00a0SE, Rhodes\u00a0JF, et\u00a0al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N\u00a0Engl J Med. 2017;377(11):1033\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"2042_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"J Mas","year":"2017","unstructured":"Mas\u00a0J, Derumeaux\u00a0G, Guillon\u00a0B, et\u00a0al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N\u00a0Engl J Med. 2017;377(11):1011\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"2042_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver\u00a0JL, Carroll\u00a0JD, Thaler\u00a0DE, et\u00a0al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N\u00a0Engl J Med. 2017;377(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"12","key":"2042_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier\u00a0B, Kalesan\u00a0B, Mattle\u00a0HP, et\u00a0al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N\u00a0Engl J Med. 2013;368(12):1083\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"2042_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan\u00a0AJ, Reisman\u00a0M, Massaro\u00a0J, et\u00a0al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N\u00a0Engl J Med. 2012;366(11):991\u20139.","journal-title":"N Engl J Med"},{"issue":"18","key":"2042_CR10","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/eurheartj\/ehy121","volume":"39","author":"Y Ahmad","year":"2018","unstructured":"Ahmad\u00a0Y, Howard\u00a0JP, Arnold\u00a0A, et\u00a0al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart\u00a0J. 2018;39(18):1638\u201349.","journal-title":"Eur Heart J"},{"issue":"21","key":"2042_CR11","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.jcin.2017.09.002","volume":"10","author":"MK Mojadidi","year":"2017","unstructured":"Mojadidi\u00a0MK, Elgendy\u00a0AY, Elgendy\u00a0IY, et\u00a0al. Transcatheter patent foramen ovale closure after cryptogenic stroke: an updated meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017;10(21):2228\u201330.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"2042_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.amjmed.2017.11.027","volume":"131","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan\u00a0M, Qamar\u00a0A, Gupta\u00a0A, et\u00a0al. Patent foramen ovale closure for secondary prevention of cryptogenic stroke: updated meta-analysis of randomized clinical trials. Am J Med. 2018;131(5):e1\u2013e10.","journal-title":"Am J Med"},{"issue":"8","key":"2042_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4244\/EIJ-D-18-00341","volume":"14","author":"D Giacoppo","year":"2018","unstructured":"Giacoppo\u00a0D, Caronna\u00a0N, Frangieh\u00a0AH, et\u00a0al. Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrombotic therapy alone: a meta-analysis. EuroIntervention. 2018;14(8):857\u201367.","journal-title":"EuroIntervention"},{"issue":"22","key":"2042_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2021.20956","volume":"326","author":"DM Kent","year":"2021","unstructured":"Kent\u00a0DM, Saver\u00a0JL, Kasner\u00a0SE, et\u00a0al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA. 2021;326(22):2277\u201386.","journal-title":"JAMA"},{"issue":"1","key":"2042_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/STROKEAHA.123.040546","volume":"55","author":"LA Sposato","year":"2024","unstructured":"Sposato\u00a0LA, Albin\u00a0CSW, Elkind\u00a0MSV, Kamel\u00a0H, Saver\u00a0JL. Patent foramen ovale management for secondary stroke prevention: state-of-the-art appraisal of current evidence. Stroke. 2024;55(1):236\u201347.","journal-title":"Stroke"},{"issue":"15","key":"2042_CR16","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.jacc.2024.07.015","volume":"84","author":"K Bonnesen","year":"2024","unstructured":"Bonnesen\u00a0K, Korsholm\u00a0K, Andersen\u00a0A, et\u00a0al. Risk of ischemic stroke after patent foramen ovale closure. J\u00a0Am Coll Cardiol. 2024;84(15):1424\u201333.","journal-title":"J Am Coll Cardiol"},{"key":"2042_CR17","unstructured":"van Dijk A, Bouma B, Hoendermis ES, et\u00a0al. Herziene leidraad percutane sluiting patent foramen ovale. Nederlandse Vereniging van Cardiologen (NVVC). 2021. https:\/\/www.nvvc.nl\/thema-kwaliteit\/richtlijnen\/default.aspx#hartklepafwijkingen. Accessed 10.10.2024."},{"issue":"4","key":"2042_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1177\/23969873231197564","volume":"8","author":"M Kneihsl","year":"2023","unstructured":"Kneihsl\u00a0M, Horner\u00a0S, Hatab\u00a0I, et\u00a0al. Long-term risk of recurrent cerebrovascular events after patent foramen ovale closure: results from a real-world stroke cohort. Eur Stroke\u00a0J. 2023;8(4):1021\u20139.","journal-title":"Eur Stroke J"},{"key":"2042_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2022.09.033","volume":"371","author":"L Abrahamyan","year":"2023","unstructured":"Abrahamyan\u00a0L, Barker\u00a0M, Dharma\u00a0C, et\u00a0al. Real world long-term outcomes among adults undergoing transcatheter patent foramen closure with Amplatzer PFO occluder. Int J Cardiol. 2023;371:109\u201315.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2042_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/17474930241298778","volume":"20","author":"B Goessinger","year":"2025","unstructured":"Goessinger\u00a0B, Greisenegger\u00a0S, Kastl\u00a0S, et\u00a0al. Stroke recurrence after transcatheter PFO closure in patients with cryptogenic stroke. Int J Stroke. 2025;20(4):450\u201360.","journal-title":"Int J Stroke"},{"issue":"3","key":"2042_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jacc.2018.10.061","volume":"73","author":"J Wintzer-Wehekind","year":"2019","unstructured":"Wintzer-Wehekind\u00a0J, Alperi\u00a0A, Houde\u00a0C, et\u00a0al. Long-term follow-up after closure of patent foramen ovale in patients with cryptogenic embolism. J\u00a0Am Coll Cardiol. 2019;73(3):278\u201387.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2042_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/17474930241281120","volume":"20","author":"H S\u00f8rensen","year":"2025","unstructured":"S\u00f8rensen\u00a0H, Grove\u00a0EL, Hojbjerg\u00a0JA, Andersen\u00a0A, Nielsen-Kudsk\u00a0JE, Simonsen\u00a0CZ. Recurrent ischemic stroke\/transient ischemic attack after patent foramen ovale closure: a\u00a0cohort study. Int J Stroke. 2025;20(2):196\u2013204.","journal-title":"Int J Stroke"},{"issue":"7","key":"2042_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","volume":"81","author":"DM Kent","year":"2013","unstructured":"Kent\u00a0DM, Ruthazer\u00a0R, Weimar\u00a0C, et\u00a0al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81(7):619\u201325.","journal-title":"Neurology"},{"issue":"3","key":"2042_CR24","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1161\/STR.0000000000000418","volume":"54","author":"HP Amin","year":"2023","unstructured":"Amin\u00a0HP, Madsen\u00a0TE, Bravata\u00a0DM, et\u00a0al. Diagnosis, workup, risk reduction of transient ischemic attack in the emergency department setting: a scientific statement from the American Heart Association. Stroke. 2023;54(3):e109\u2013e21.","journal-title":"Stroke"},{"issue":"7","key":"2042_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011652","volume":"15","author":"A Alperi","year":"2022","unstructured":"Alperi\u00a0A, Guedeney\u00a0P, Horlick\u00a0E, et\u00a0al. Transcatheter closure of patent foramen ovale in older patients with cryptogenic thromboembolic events. Circ Cardiovasc Interv. 2022;15(7)e011652.","journal-title":"Circ Cardiovasc Interv"},{"issue":"Suppl 2","key":"2042_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.2274","volume":"44","author":"CH Hamm","year":"2023","unstructured":"Hamm\u00a0CH, Hamm\u00a0C, Doerr\u00a0O, Gruen\u00a0D. Long term follow-up of patent foramen closure due to embolic infarction in elderly patients. Eur Heart\u00a0J. 2023;44(Suppl 2)ehad655.2274.","journal-title":"Eur Heart J"},{"issue":"12","key":"2042_CR27","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00392-023-02263-8","volume":"112","author":"D Jurczyk","year":"2023","unstructured":"Jurczyk\u00a0D, Macherey-Meyer\u00a0S, Rawish\u00a0E, et\u00a0al. New-onset atrial fibrillation after percutaneous patent foramen ovale closure: a meta-analysis. Clin Res Cardiol. 2023;112(12):1824\u201334.","journal-title":"Clin Res Cardiol"},{"key":"2042_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.06.007","volume":"387","author":"D Trabattoni","year":"2023","unstructured":"Trabattoni\u00a0D, Gili\u00a0S, Calligaris\u00a0G, et\u00a0al. Patent foramen ovale closure with the Occlutech Figulla flex II device: A long-term (up to 10-years) follow-up. Int J Cardiol. 2023;387:131116.","journal-title":"Int J Cardiol"},{"key":"2042_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2022.09.033","volume":"371","author":"L Abrahamyan","year":"2023","unstructured":"Abrahamyan\u00a0L, Barker\u00a0M, Dharma\u00a0C, et\u00a0al. Real world long-term outcomes among adults undergoing transcatheter patent foramen closure with amplatzer PFO occluder. Int J Cardiol. 2023;371:109\u201315.","journal-title":"Int J Cardiol"},{"issue":"36","key":"2042_CR30","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1093\/eurheartj\/ehad305","volume":"44","author":"CV Skibsted","year":"2023","unstructured":"Skibsted\u00a0CV, Korsholm\u00a0K, Pedersen\u00a0L, Bonnesen\u00a0K, Nielsen-Kudsk\u00a0JE, Schmidt\u00a0M. Long-term risk of atrial fibrillation or flutter after transcatheter patent foramen ovale closure: a\u00a0nationwide Danish study. Eur Heart\u00a0J. 2023;44(36):3469\u201377.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-026-02042-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:48:36Z","timestamp":1776422916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-026-02042-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2042"],"URL":"https:\/\/doi.org\/10.1007\/s12471-026-02042-w","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W.\u00a0Kanon, E.S.\u00a0Hoendermis, E.A.\u00a0Badings and J.\u00a0van Wijngaarden declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}